Benzinga | Oct 28, 2021 06:59AM EDT

Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform, Raises Price Target to $32

Oppenheimer analyst Justin Kim downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Perform and raises the price target from $28 to $32.